# Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder

> **NCT00209807** · PHASE4 · UNKNOWN · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 42 (estimated)

## Conditions studied

- Major Depression
- Pain
- Abdominal Pain

## Interventions

- **DRUG:** escitalopram
- **DRUG:** Reboxetine
- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT00209807
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-09
- **Primary completion:** 2009-06
- **Final completion:** 2011-04
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2010-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00209807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00209807, "Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00209807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*